Oral Cannabis for Chronic Spine Pain
This study is looking at how well oral cannabis solutions can help people with long-lasting back or neck pain. Researchers want to see if solutions containing THC/CBD or just THC can reduce pain and help people lower their use of opioid medications. You might be able to join if you are between 21 and 84 years old and have had chronic spine pain for at least three months. The study will measure changes in your pain levels using a Visual Analog Scale (VAS) and track any changes in your opioid dose over several weeks. The study is currently unclear on its recruitment status and plans to enroll 157 participants.
- Study design
- This is a randomized, placebo-controlled study with two main parts, involving a total of 157 participants. One part uses a crossover design where participants receive different treatments at different times, and the other uses a parallel design where participants receive one treatment throughout.
- What's involved
- You would need to stop using cannabis (medical or recreational) for 14 days before starting the study and throughout your participation. Your pain levels and opioid doses will be measured weekly for up to 22 weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your pain and opioid dose will be measured weekly for up to 22 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Safety and Efficacy of Oral Cannabis in Chronic Spine Pain
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Emily Lindley, PhD · PRINCIPAL_INVESTIGATOR · University of Colorado, Denver
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Change in chronic pain as measured by the Visual Analog Scale (VAS) for painWeekly, up to week 22
The Visual Analog Scale (VAS) for pain is a 0-100mm visual scale anchored by "no pain" and "worst possible pain".
- Change in opioid dose as measured in morphine milligram equivalents (MME)Weekly, up to week 22